Get all premium features to the best stock analysis tool

CEL-SCI Reports Fiscal First Quarter 2026 Results

VIENNA, Va.--(BUSINESS WIRE)---- $CVM #Multikine--CEL-SCI reported financial results for three months ended December 31, 2025, as well as key recent clinical and corporate developments.

CEL-SCI Reports Fiscal 2025 Results

VIENNA, Va.--(BUSINESS WIRE)---- $CVM #Multikine--CEL-SCI Corporation reports financial results for the fiscal year ended September 30, 2025, as well as key clinical and corporate developments.

CEL-SCI Presentation at LD Micro "Main Event" Available on Tuesday, October 21, 2025

Vienna, Virginia--(Newsfile Corp. - October 20, 2025) - CEL-SCI Corporation (NYSE American: CVM), a clinical stage cancer immunotherapy company, previously announced that Geert Kersten, Chief Executive Officer, is scheduled to present at the LD Micro "Main Event" Investor Conference on October 21, 2025. You can register to watch the virtual presentation at 9:30 a.m.

CEL-SCI Announces Closing of $5.7 Million Offering Priced At-The-Market Under NYSE American Rules

VIENNA, Va.--(BUSINESS WIRE)---- $CVM #Multikine--CEL-SCI announces closing of $5.7 million offering priced at-the-market under NYSE American rules.